Comera SPAC Presentation Deck
CLS-002: Targeting Large Addressable Market
with a First-in-Class SQ Formulation
Second program targets a highly growing space within immuno-oncology
Program
Therapeutic Area
Development Status
Key Milestone
Competition
Peak Sales Potential
SQ formulation of marketed 1-0 mAb
Oncology
Formulation development
insights/delivering-innovation-2020-oncology-market-outlook;
IND filing: Q3 2024
No SQ available
$500M-$800M base case
Global Revenue ($B)
200
160
120
80
40
0
62.2
71.5
lobal 1-O Market*
Revenue in billions (USD)
82.3
Source: https://www.biospace.com/article/immuno-oncology-therapy-market-a-paradigm-shift-from-traditional-chemotherapies-to-immunotherapies-is-propelling-the-overall-market-growth/;
94.6
108.8
ň
Year
https://www.businesswire.com/news/home/20210929005402/en/Immuno-Oncology-Drugs-Global-Market-Report-2021---Research And Markets.com; https://www.mckinsey.com/industries/life-sciences/our-
https://www.marketwatch.com/press-release/immuno-oncology-market-size-share-key-players-growth-analysis-and-forecast-2028-2021-12-06;
https://www.futurewise research.com/healthcare-market-research/Immuno-Oncology-Market/10981; Peak sales potential reflects maximum estimated sales in a 12-month period following approval.
Comera
125.1
143.9
LIFE SCIENCES
2020 2021 2022 2023 2024 2025 2026 2027 2028
165.5
190.3
24View entire presentation